/ Weight Loss Treatment Affinity Patient Since 2023 Read review *Patient weight loss results are not typical
Week-by-week dose schedule table This table provides the standard schedule
Enter the Dual and Triple Agonists To break through this ceiling, scientists began combining hormone targets: Dual Agonists (GLP-1 + GIP): Tirzepatide (Mounjaro, Zepbound) was the first commercially approved dual agonist
February 9, 2026: PlushCare was removed from this list after changes to its product range
PlexusDx intake screening captures medical history, current medications, and contraindications before recommending any medication, ensuring personalized safety assessment
Among those who stopped, 24% cited side effects and 28% said they had reached their target weight